BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31965687)

  • 1. Intravenous immunoglobulin in resistant livedoid vasculopathy: Analysis of a case series.
    Ozden MG; Ozdemir H; Şenturk N
    Dermatol Ther; 2020 Mar; 33(2):e13229. PubMed ID: 31965687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intravenous immunoglobulins in livedoid vasculopathy: long-term follow-up of 11 patients.
    Monshi B; Posch C; Vujic I; Sesti A; Sobotka S; Rappersberger K
    J Am Acad Dermatol; 2014 Oct; 71(4):738-44. PubMed ID: 25022849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment for Livedoid Vasculopathy: A Systematic Review.
    Micieli R; Alavi A
    JAMA Dermatol; 2018 Feb; 154(2):193-202. PubMed ID: 29141075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulsed intravenous immunoglobulin therapy in refractory ulcerated livedoid vasculopathy: seven cases and a literature review.
    Kim EJ; Yoon SY; Park HS; Yoon HS; Cho S
    Dermatol Ther; 2015; 28(5):287-90. PubMed ID: 25845419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Livedoid Vasculopathy: A French Observational Study Including Therapeutic Options.
    Gardette E; Moguelet P; Bouaziz JD; Lipsker D; Dereure O; Le Pelletier F; Lok C; Maisonobe T; Bessis D; Conard J; Francès C; Barete S
    Acta Derm Venereol; 2018 Oct; 98(9):842-847. PubMed ID: 29738044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Livedoid vasculopathy - current aspects of diagnosis and treatment of cutaneous infarction.
    Kerk N; Goerge T
    J Dtsch Dermatol Ges; 2013 May; 11(5):407-10. PubMed ID: 23437985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case of livedoid vasculopathy with peripheral neuropathy successfully treated with low-dose warfarin.
    Osada S; Kimura Y; Kawana S
    J Dermatol; 2010 Jan; 37(1):98-101. PubMed ID: 20175830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel use of intermittent low dose dabigatran for maintenance of remission in livedoid vasculopathy.
    Rajan M B; Bhardwaj A; Bharti JN; Agrawal A
    Dermatol Ther; 2021 Jul; 34(4):e14997. PubMed ID: 34028946
    [No Abstract]   [Full Text] [Related]  

  • 9. Intravenous immunoglobulins in difficult-to-treat ulcerated livedoid vasculopathy: five cases and a literature review.
    Bounfour T; Bouaziz JD; Bézier M; Petit A; Viguier M; Rybojad M; Bagot M
    Int J Dermatol; 2013 Sep; 52(9):1135-9. PubMed ID: 23488633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous Immunoglobulin Therapy in Livedoid Vasculopathy: Retrospective Observation of Clinical Outcome and Patient's Activity Level.
    Kofler K; Strölin A; Geiger V; Kofler L
    J Cutan Med Surg; 2021 Sep; 25(5):504-510. PubMed ID: 33779349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Livedoid vasculopathy. Pathogenesis, diagnosis and treatment of cutaneous infarction].
    Goerge T
    Hautarzt; 2011 Aug; 62(8):627-34; quiz 635. PubMed ID: 21786003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of new low-dose oral anticoagulants in recalcitrant livedoid vasculopathy.
    Furukawa F; Mizawa M; Makino T; Shimizu T
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28739563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Livedoid vasculopathy in a patient with lupus anticoagulant and MTHFR mutation: treatment with low-molecular-weight heparin.
    Abou Rahal J; Ishak RS; Otrock ZK; Kibbi AG; Taher AT
    J Thromb Thrombolysis; 2012 Nov; 34(4):541-4. PubMed ID: 22592843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Livedoid vasculopathy; favorable clinical response with low dose warfarin.
    Nakamura S; Kishibe M; Nishi K; Hashimoto Y; Takeda K; Mizumoto T; Iizuka H
    Eur J Dermatol; 2011; 21(6):1011-2. PubMed ID: 21914587
    [No Abstract]   [Full Text] [Related]  

  • 15. What caused this painful skin erosion? Livedoid vasculopathy.
    Monroe JR
    JAAPA; 2012 May; 25(5):20. PubMed ID: 22712143
    [No Abstract]   [Full Text] [Related]  

  • 16. Response of livedoid vasculopathy to rivaroxaban.
    Winchester DS; Drage LA; Davis MD
    Br J Dermatol; 2015 Apr; 172(4):1148-50. PubMed ID: 25255997
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment of Livedoid Vasculopathy With Rivaroxaban: A Potential Use of New Oral Anticoagulants for Dermatologists.
    Jiménez-Gallo D; Villegas-Romero I; Rodríguez-Mateos ME; Linares-Barrios M
    Actas Dermosifiliogr (Engl Ed); 2018 Apr; 109(3):278-281. PubMed ID: 29074145
    [No Abstract]   [Full Text] [Related]  

  • 18. The management of livedoid vasculopathy focused on direct oral anticoagulants (DOACs): four case reports successfully treated with rivaroxaban.
    Franco Marques G; Criado PR; Alves Batista Morita TC; Cajas García MS
    Int J Dermatol; 2018 Jun; 57(6):732-741. PubMed ID: 29663354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Livedoid vasculopathy: an in-depth analysis using a modified Delphi approach.
    Alavi A; Hafner J; Dutz JP; Mayer D; Sibbald RG; Criado PR; Senet P; Callen JP; Phillips TJ; Romanelli M; Kirsner RS
    J Am Acad Dermatol; 2013 Dec; 69(6):1033-1042.e1. PubMed ID: 24028907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Vasculitis and vasculopathy].
    Marković A
    Acta Med Croatica; 2012 Oct; 66 Suppl 1():19-24. PubMed ID: 23193816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.